Skip to content
Emcure Pharmaceuticals logo

Emcure Pharmaceuticals IPO

MainboardListedDiversified & Others
Check allotment status
Issue price
₹1,008
Listing price
₹1,325.05
+31.45%
Current price
₹2,361.7
+134.30%
Subscribed
68.41x
Issue size
₹1,952.03 Cr
Listed on
10 Jul 2024

IPO timeline

  1. Opens
    3 JulWed
  2. Closes
    5 JulFri
  3. Allotment
    8 JulMon
  4. Refunds
    9 JulTue
  5. Demat credit
    9 JulTue
  6. Listing
    10 JulWed

Issue details

Price band
₹960 – ₹1,008 per share
Issue size
₹1,952.03 Cr
Fresh issue
Not available
Offer for sale
Not available
Issue type
Fresh capital cum OFS
Face value
₹10 per share
Lot size
14 shares
Minimum investment
₹14,112
Listing on
BSE, NSE
Exchange code
EMCURE · 544210

This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.

Lot size and investment

ApplicationLotsSharesAmount
Retail (Min)114₹14,112
Retail (Max)14196₹1,97,568
S-HNI (Min)15210₹2,11,680
B-HNI (Min)71994₹10,01,952

Reservation

QIB
96,33,084 shares (50.00% of the Offer)
NII
28,89,926 shares (15.00% of the Offer)
Retail
67,43,160 shares (35.00% of the Offer)
Employee
1,08,900 shares (0.56% of the Offer)

Allotment status

Registrar: MUFG Intime India Private Limited

The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).

Check allotment on MUFG Intime India
  1. 1Open the registrar's allotment page and select this IPO from the list.
  2. 2Enter your PAN, application number or DP / Client ID.
  3. 3Submit to see the number of shares allotted, if any.
Basis of allotment
8 Jul 2024
Refunds initiated
9 Jul 2024
Shares credited to demat
9 Jul 2024
Listing
10 Jul 2024

Grey market premium (GMP)

Updated 09 Jul 2024, 12:00 PM IST
Current GMP
₹360
+36.00%
Estimated listing price
₹1,368
Issue price ₹1,008
Highest
₹365
8 Jul
Lowest
₹250
29 Jun

GMP by day (₹ per share)

Day-wise GMP table
DateGMPPremiumEst. listing
9 Jul 2024₹360+36.00%₹1,368
8 Jul 2024₹365+36.00%₹1,373
6 Jul 2024₹355+35.00%₹1,363
5 Jul 2024₹320+32.00%₹1,328
4 Jul 2024₹310+31.00%₹1,318
3 Jul 2024₹282+28.00%₹1,290
2 Jul 2024₹275+27.00%₹1,283
1 Jul 2024₹260+26.00%₹1,268
29 Jun 2024₹250+25.00%₹1,258
Kostak rate
₹0

GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.

Subscription status

Updated 10 Nov 2026, 06:44 AM IST
Overall subscription
68.41x
Fully subscribed
  • QIB191.24x
  • NII (HNI)49.32x
  • Retail7.36x
  • Employee8.81x

Financials

Amounts in Rs. Crore
P/E Ratio
36.07
EPS (₹)
27.95
RoE
16.90%
RoCE
19.37%
RoNW
16.87%
PAT Margin
7.86%
Debt / Equity
0.67
NAV (₹)
163.22

Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.

Period ended31 Mar 202431 Mar 202331 Mar 2022
Assets7,806.166,672.536,063.47
Total Income6,715.246,031.725,918.86
Profit After Tax527.58561.85702.56
NET Worth2,952.282,501.131,987.55
Total Borrowing2,091.942,202.422,102.19
CompanyIssue sizeP/ERoNWPAT marginSubscribedListing gain
Emcure Pharmaceuticals
This IPO
₹1,952.03 Cr36.0716.87%7.86%68.41x+31.45%
Urban Company
Mainboard · listed 17 Sep 2025
₹1,900 Cr61.6813.35%—108.96x+57.52%
Allied Blenders & Distillers
Mainboard · listed 2 Jul 2024
₹1,500 Cr1393.871.03%0.17%24.77x+13.88%
Dr. Agarwal's Health Care
Mainboard · listed 4 Feb 2025
₹3,027.26 Cr160.486.21%6.90%1.49x0.00%
DOMS Industries
Mainboard · listed 20 Dec 2023
₹1,200 Cr32.4328.39%2.51%98.51x+77.22%
DAM Capital Advisors
Mainboard · listed 27 Dec 2024
₹840.25 Cr28.3744.98%38.75%81.88x+38.87%
Anand Rathi Share & Stock Brokers
Mainboard · listed 30 Sep 2025
₹745 Cr25.0623.12%12.23%21.8x+4.35%

Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.

IPO objectives

₹841.14 Cr total

How Emcure Pharmaceuticals plans to use the money raised, as stated in the offer document.

  1. Repayment and/or prepayment of all or a portion of certain outstanding borrowings availed by our Company₹800 Cr
  2. General corporate purposes₹41.14 Cr

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited was incorporated as Emcure Pharmaceuticals Private Limited on 16 April 1981. It is an Indian pharmaceutical company that develops, makes and markets a broad range of products across major therapy areas. It is research driven, with a portfolio of orals, injectables and biotherapeutics that reaches over 70 countries, with a strong presence in India, Europe and Canada. In India it works across acute and chronic therapy areas, including gynaecology, cardiovascular, vitamins and minerals and HIV antivirals. Its promoters include Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar and Samit Satish Mehta. The IPO was Rs 1,952.03 crore, with Rs 800.58 crore of fresh issue and Rs 1,151.45 crore of offer for sale, mostly by BC Investments IV, with promoters and promoter group members also selling. Rs 800.00 crore was planned for repaying borrowings.

Strengths

  • Total income rose from Rs 5,918.86 crore in FY2022 to Rs 6,715.24 crore in FY2024.
  • Rs 800.00 crore of the fresh issue was planned for repaying debt.
  • It sells in over 70 countries, with a strong presence in India, Europe and Canada.
  • Net worth grew from Rs 1,987.55 crore on 31 March 2022 to Rs 2,952.28 crore on 31 March 2024.
  • The source puts return on net worth at 16.87%.

Risks

  • Profit after tax fell from Rs 702.56 crore in FY2022 to Rs 527.58 crore in FY2024.
  • The pre-issue P/E was 34.55 at the upper band of Rs 1,008, based on EPS of Rs 29.17.
  • Total borrowing was Rs 2,091.94 crore on 31 March 2024.
  • Rs 1,151.45 crore of the issue was offer for sale, and overseas markets add regulatory and currency risk.
  • Promoters and the promoter group held 83.21% before the issue and about 78.24% after it, as per the RHP share counts.

Promoters and shareholding

Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar and Samit Satish Mehta

Promoter holding, pre-issue
83.21%
Promoter holding, post-issue
78.24%

Anchor investors

48 investors · ₹582.65 Cr raised
InvestorShares allottedAmount% of anchor book
SBI MAGNUM CHILDRENS BENEFIT FUND - INVESTMENT PLAN2,38,098₹24 Cr4.12%
SBI HEALTHCARE OPPORTUNITIES FUND59,514₹6 Cr1.03%
HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND99,204₹10 Cr1.72%
HDFC MUTUAL FUND - HDFC DIVIDEND YIELD FUND99,204₹10 Cr1.72%
HDFC MUTUAL FUND - HDFC BUSINESS CYCLE FUND57,862₹5.83 Cr1%
HDFC MUTUAL FUND - HDFC MANUFACTURING FUND41,342₹4.17 Cr0.72%
ICICI PRUDENTIAL PHARMA HEALTHCARE & DIAGNOSTICS (P.H.D.) FUND2,97,612₹30 Cr5.15%
ABU DHABI INVESTMENT AUTHORITY - MONSOON2,85,208₹28.75 Cr4.93%
GOLDMAN SACHS FUNDS- GOLDMAN SACHS INDIA EQUITY PORTFOLIO2,85,208₹28.75 Cr4.93%
NOMURA INDIA INVESTMENT FUND MOTHER FUND2,85,208₹28.75 Cr4.93%
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - IIFL ASSET MANAGEMENT LIMITED1,96,322₹19.79 Cr3.4%
WHITEOAK CAPITAL FLEXI CAP FUND1,14,982₹11.59 Cr1.99%
WHITEOAK CAPITAL MULTI CAP FUND36,330₹3.66 Cr0.63%
WHITEOAK CAPITAL PHARMA AND HEALTH CARE FUND35,560₹3.58 Cr0.62%
WHITEOAK CAPITAL ELSS TAX SAVER FUND9,450₹0.95 Cr0.16%
ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND89,040₹8.98 Cr1.54%
ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C ADITYA BIRLA SUN LIFE RETIREMENT FUND THE 30S PLAN57,708₹5.82 Cr1%
ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C ADITYA BIRLA SUN LIFE BAL BHAVISHYA YOJNA49,574₹5 Cr0.86%
AXIS MUTUAL FUND TRUSTEE LTD. A/C AXIS MUTUAL FUND A/C AXIS BALANCED ADVANTAGE FUND71,246₹7.18 Cr1.23%
AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL FUND A/C AXIS BUSINESS CYCLES FUND63,322₹6.38 Cr1.1%
AXIS MUTUAL FUND TRUSTEE LTD A/C AXIS MUTUAL FUND A/C AXIS FLEXI CAP FUND39,592₹3.99 Cr0.69%
AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL FUND A/C AXIS EQUITY SAVER FUND22,162₹2.23 Cr0.38%
HDFC LIFE INSURANCE COMPANY LIMITED1,96,322₹19.79 Cr3.4%
ICICI PRUDENTIAL LIFE INSURANCE COMPANY LIMITED1,96,322₹19.79 Cr3.4%
KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK MANUFACTURE IN INDIA FUND1,47,238₹14.84 Cr2.55%
KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK HEALTHCARE FUND49,084₹4.95 Cr0.85%
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA RETIREMENT FUND - WEALTH CREATION SCHEME1,96,322₹19.79 Cr3.4%
MIRAE ASSET HEALTHCARE FUND1,96,322₹19.79 Cr3.4%
SBI LIFE INSURANCE COMPANY LIMITED1,96,322₹19.79 Cr3.4%
AMUNDI FUNDS NEW SILK ROAD1,36,794₹13.79 Cr2.37%
DSP HEALTHCARE FUND1,36,794₹13.79 Cr2.37%
FRANKLIN INDIA OPPORTUNITIES FUND1,36,794₹13.79 Cr2.37%
MORGAN STANLEY INDIA INVESTMENT FUND INC.1,36,794₹13.79 Cr2.37%
NEUBERGER BERMAN EMERGING MARKETS EQUITY FUND1,36,794₹13.79 Cr2.37%
PICTET - INDIAN EQUITIES1,36,794₹13.79 Cr2.37%
THELEME INDIA MASTER FUND LIMITED1,36,794₹13.79 Cr2.37%
THE PRUDENTIAL ASSURANCE COMPANY LIMITED1,36,794₹13.79 Cr2.37%
UTI - HEALTHCARE FUND1,36,794₹13.79 Cr2.37%
BAJAJ ALLIANZ LIFE INSURANCE COMPANY LTD.83,703₹8.44 Cr1.45%
BANDHAN MIDCAP FUND83,703₹8.44 Cr1.45%
CANARA ROBECO MUTUAL FUND A/C CANARA ROBECO VALUE FUND83,703₹8.44 Cr1.45%
EAMC ICAV - ENAM INDIA OPPORTUNITIES FUND83,703₹8.44 Cr1.45%
EDELWEISS TRUSTEESHIP CO LTD AC-EDELWEISS MF AC - EDELWEISS RECENTLY LISTED IPO FUND83,703₹8.44 Cr1.45%
INVESCO INDIA EQUITY FUND83,703₹8.44 Cr1.45%
KOTAK FUNDS-INDIA MIDCAP FUND83,703₹8.44 Cr1.45%
MAX LIFE INSURANCE COMPANY LIMITED83,703₹8.44 Cr1.45%
MOTILAL OSWAL LARGE CAP FUND83,703₹8.44 Cr1.45%
3P INDIA EQUITY FUND 1M83,697₹8.44 Cr1.45%

Registrar, lead managers and documents

Emcure Pharmaceuticals IPO: common questions

1.When does the Emcure Pharmaceuticals IPO open and close?

The Emcure Pharmaceuticals IPO opens on 3 Jul 2024 and closes on 5 Jul 2024.

2.What is the price band of the Emcure Pharmaceuticals IPO?

The price band is ₹960 – ₹1,008 per share, with a lot size of 14 shares and a minimum investment of ₹14,112.

3.What is the size of the Emcure Pharmaceuticals IPO?

The issue size is ₹1,952.03 Cr (Fresh capital cum OFS).

4.What is the GMP of the Emcure Pharmaceuticals IPO?

The last reported grey market premium is ₹360 per share as of 09 Jul 2024, 12:00 PM IST. GMP is unofficial and changes frequently.

5.When is the Emcure Pharmaceuticals IPO allotment?

The basis of allotment is expected on 8 Jul 2024. Allotment status can be checked with the registrar, MUFG Intime India Private Limited.

6.When will the Emcure Pharmaceuticals IPO list?

The shares listed on 10 Jul 2024 on BSE, NSE.

7.Who is the lead manager of the Emcure Pharmaceuticals IPO?

The book running lead managers are Axis Capital, Kotak Mahindra Capital Company Limited, Jefferies India Private Limited, JP Morgan India Pvt. Ltd, and the registrar is MUFG Intime India Private Limited.

8.What will the money raised in the Emcure Pharmaceuticals IPO be used for?

As stated in the offer document, the proceeds are for: Repayment and/or prepayment of all or a portion of certain outstanding borrowings availed by our Company; General corporate purposes.

9.How can my company launch an IPO like Emcure Pharmaceuticals?

Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.

For business owners

Your company could be the next listing

Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.

  • Eligibility check against NSE Emerge, BSE SME and Main Board norms
  • Indicative valuation and issue size for your business
  • A clear timeline from readiness to listing day

Check if your business can list

Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.

Prefer to talk? Call +91 92130 20393